Key facts
- Caligan Partners LP filed SCHEDULE 13G for Verrica Pharmaceuticals Inc. Common stock, $0.0001 par value per share (VRCA).
- Disclosed ownership: 10%.
- Date of event: 31 Dec 2024.
Caligan Partners LP - 31 Dec 2024 SCHEDULE 13G Report for Verrica Pharmaceuticals Inc. Common stock, $0.0001 par value per share (VRCA)
- Filing Manager
- Caligan Partners LP
- Reporting Manager
- Caligan Partners LP
- Symbol
- VRCA
- Shares outstanding
- 158,725,255 shares
- Disclosed Ownership
- 15,856,653 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G
- Filing time
- 12 Feb 2025, 16:05:38 UTC
- Date of event
- 31 Dec 2024
- SEC
- View on sec.gov
Key filing fact
Caligan Partners LP disclosed 10% ownership in Verrica Pharmaceuticals Inc. Common stock, $0.0001 par value per share (VRCA) on 31 Dec 2024.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 12 Feb 2025, 16:05.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Caligan Partners LP | 10% | 15,856,653 | 0 | 15,856,653 | /s/ David Johnson | David Johnson, Managing Partner | |
| David Johnson | 10% | 15,856,653 | 0 | 15,856,653 | /s/ David Johnson | David Johnson, Individually |
CIK / CUSIP context first